





PHARMACEUTICAL GRADE

DISCLAIMER

This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

Q4 FY25 OVERVIEW



Q4 FY25 OVERVIEW

Multiple contract wins: +€3.2m (A$5.8m) supply agreement with maiden German client and A$7m Exclusive with NectarTek Australia

Upgraded Guidance to **$28.0m revenue in FY25** and delivered $29.3m revenue, due solely to expansion in AUS market

Doubled GMP Flower Packing Capacity to 30tn in push towards **25% Australian market share** in FY26

Certificate of GMP compliance with Europe, Canada, Singapore & UK allowing export to these markets

Record quarterly Cash Receipts of **$10.7 million** and representing a **302% increase** on Q4 FY24 and a 26% increase on Q3 FY25

Record quarterly revenue of **$9.5 million** delivered representing a **204% increase** on Q4 FY24 and a 33% increase on Q3 FY25

$7.6m cash on balance sheet to fund multiple growth initiatives throughout FY26

Continued development and execution of the company's strategic entries into European and UK markets

(1) H2 FY25 Revenue remains draft and subject to full year audit

FINANCIALS



REVENUE GROWTH

Record quarterly revenue of $9.5 million delivered, representing a 204% increase on Q4 FY24 & a 33% increase on Q3 FY25

- Record quarterly revenue of $9.5 million delivered
  - 204% increase on Q4 FY24 (**PCP**)
  - 33% increase on Q3 FY25
- Key Drivers of growth: In FY25, Australian medical cannabis operations was the sole contributor, including new contract wins and existing clients moving their manufacturing across to BLS.
- Key Drivers of growth in FY26: Significant growth potential in our home market, where we plan to double our market share in key product lines in FY26.
- The €3.2 million contract with Germany made no contribution to the final months of the quarter and Financial Year. We expect to see most of the minimum contracted volume sold and delivered in H1 FY26.
- UK supply Agreements expected to deliver $2.5m in H1FY26.



REVENUE GROWTH

Revenue for the half represents a substantial increase of 33.2% increase on H1 FY25A revenue[1]

- Unaudited FY25 Revenue totalled $29.3 million, representing:
  - A 214% increase on FY24 revenue of $9.3m
  - Exceeding FY25 revenue guidance of $28 million by $1.3 million, a 4.6% increase
  - Unaudited revenue of $16.7m in H2 FY25 represents a 33.2% increase on H1 FY25 revenue of $12.6m[1]
- This material revenue growth, in conjunction with firm GP margins and limited overhead expansion is anticipated to deliver solid earnings in the FY25 full year result
- Revenue growth continues to be strong, with substantial further growth expected in FY26, to be encompassed in guidance provided at the full year results.



CASH FLOW POSITIVE

The Company recorded the fourth consecutive positive cashflow period, continuing to drive consistent profitability

- Record quarterly Cash Receipts of $10.7 million, representing:
  - A 302% increase on PCP
  - A 26% increase on Q3 FY25
- Cash from operations was $1.55 million in Q4 FY25 with further investment in working capital required to meet the growing trajectory of the business.
- A minor reduction in comparative operating cash flow because of increased investment in inventory, with demand building throughout the quarter and into FY26.
- This represents the fourth consecutive positive cash flow generating quarter for the business.
- $0.3 million was invested in operating plant & equipment, security vaults and leasehold improvements to increase manufacturing and storage capacity and systems.
- Cash at the end of the quarter was $7.6 million.



AUSTRALIAN MARKET GROWTH



PRODUCTION CAPACITY

Recent investment into additional equipment & facilities has underpinned a substantial increased production capability & will continue to simultaneously underpin the initial rollout of EU & UK strategy

CURRENT AUSTRALIAN MANUFACTURING CAPACITY[1]

SKU	THC FLOWER*	THC & CBD PASTILLES	VAPES	ORAL LIQUIDS & OILS
CAPACITY - REVENUE PER DAY	~$83,000*	~$227,000	~$58,000	~$72,000
ANUNUALISED CAPACITY	~$21.0m pa	~$57m pa	~$15m pa	~$18m pa
TOTAL CAPACITY	$111M P.A.			

*Flower capacity figures assume 10g-15g pack sizes. Germany and UK order 500g pack sizes. Daily revenue figure excludes flower resale value.

KEY METRICS

+1.0m
Finished Medicines Manufactured LTM

15m
Individual Pastilles in Last 12-months

+12,000kg*
of Cannabis Flower Packed FY25

+110k
Finished Products Per-month, current

30,000kg*
Increased flower capacity in FY26

25%
Targeting 25% of Australia's Medicinal Cannabis Flower Market

+300m²
Of Clean room manufacturing

+400m²
Of Controlled Drug Storage

(1) Assumes operating at full capacity across 252 days a year

AUSTRALIAN GROWTH STRATEGY

Australian medicinal cannabis prescriptions continue to grow. BXN will continue to aggressively invest in growing domestic market share

AUSTRALIAN MEDICINAL CANNABIS APPROVALS[1]



- Market projections suggest that the edible segment, including pastilles, could grow from 1% of the Australian medical cannabis market to more than 20% by 2030.
- GMP-certified THC & CBD pastilles in Australia are emerging as one of the most popular delivery methods for medical cannabis.
- Bioxyne is continuing to benefit significantly from a growth in demand for cannabis pastilles as a dose form.

AUSTRALIAN MARKET GROWTH STRATEGY

Australia has surpassed 1.3m patients, with total AP authorities ~1.3m and continued growth in the SAS-B pathway (expected ~20% YoY growth from 2024 to 2025)

In FY25 BLS manufactured and deliver +1.0m CBMPs, whilst the Australian market consumed an estimated 12m products, highlighting the significant opportunity for domestic growth

Current revenue run-rate of c$3.0m per-month in Australia, which continues to grow via new and existing customer growth and expansion of the Australian market.

Our strategic focus is to replicate our success in Australia in Europe and the UK. We plan to do this organically, rather than through acquisitions.

(1) Australian Federal Health Department:; (2) TGA.gov.au; (3) Cannabiz; (4)MJBiz Daily

AUSTRALIAN MARKET GROWTH



EU MARKET ENTRY

Czechia facility to supply rapidly growing European markets with construction beginning imminently

BUILD MANUFACTURING & CONTROLLED SUSTANCE SUPPLY CAPABILITY

CZECH FACILITY TARGET COMPLETION IN CY26

TARGETING 5-10% OF GERMAN MEDICAL CANNABIS FLOWER IN FY26

GERMAN MEDICINAL CANNABIS PATIENTS & FLOWER



GERMAN TAM & PRICING



PURSUE STRATEGIC ENTRIES

GERMANY[2,3]



Germany is expected to consume 150tons of Medical Cannabis flower in 2025, surpassing €1 billion in sales.

BLS is targeting the B2B Flower Market and expects to supply 10 tons to Germany in FY26

FIRST CONTRACTS SIGNED IN Q4

(1) Prohibition Partners; (2) PubMed; (3) European Union Drugs Agency

UK MARKET ENTRY

The UK represents a material opportunity for the Company with the replication of the existing QLD facility set to supply a rapidly growing market with similar customer dynamics

Q1 FY26 – ESTABLISH DISTRIBUTION

UNITED KINGDOM

2m+
MONTHLY CANNABIS USERS

4
Import & Distribution Partnerships signed

18
BLS CBPMs registered with Home Office & MHRA

+$2.5m
Value of first shipment of CBPMs to UK from Aus

10
Clinics finalizing commercial terms representing 60k patients

CURRENT ADDRESSABLE MARKET FOR BLS ~£82M (A$160M)

UK MEDICAL CANNABIS PATIENTS & CUSTOMER VALUE



UK MEDICAL CANNABIS PATIENTS & CUSTOMER VALUE



BUILD LEADING SUPPLY CAPABILITY

UK Manufacturing & Distribution Facility (similar to BLS QLD), holding GMP and Schedule 1&2 narcotics license. Facility will be eligible for a 20% CAPEX refund from UK Government

(1) Horizon Research; (2)ITIJ.com and Company Market Research


BREATHE LIFE SCIENCES

OUTLOOK

Substantial growth anticipated in FY26 with multiple growth drivers underpinning revenue & margin expansion

EUROPE

Continue to accelerate controlled drugs and GMP manufacturing accreditation in Czechia to serve EU markets

UK

Continue to progress controlled drugs and GMP manufacturing accreditation in the UK. Working with local government to secure grant funding and tax breaks

AUS

Invest in inventory to meet significant international and Australian demand and to continue driving sales growth

Continue to assess strategic acquisition opportunities that may fast-track supply capability into key regions

Continue to expand supply opportunities for MDMA and Psilocybin with potential supply into France, UK, and Australia

The Board intends on providing FY26 guidance at the release of the FY25 results next month

APPENDIX

BOARD & MANAGEMENT



Mr. Anthony Ho
B. Com (UNSW), CA, FAICD, FCIS, FGIA
Non-executive Chairman

- Tony is an experienced company director and is currently a director and chairman of a number of listed ASX companies.
- Tony was executive director of sales and distribution company Arthur Yates & Co Limited, as well as Finance Director/CFO of listed retailers on the ASX – M. S. McLeod Holdings Limited (Downtown Duty Free), Galore Group Limited (Barbeques Galore) and Brazin Limited (Bras N Things, Sanity Music).
- Prior to joining commerce, Tony was a partner of Cox Johnston & Co, Chartered Accountants which has since merged with Ernst & Young.

Samuel Watson
BSc Finance and Economics
Managing Director

- Samuel Watson was appointed to the Board on 19 May 2023.
- Sam is the founder and CEO of Breathe Life Sciences (BLS). Since establishing BLS and the Dr Watson® Brand in 2018, BLS quickly became a significant player in the health and wellness industry in Europe, UK and Japan. In 2020, BLS entered the Australian market and has grown rapidly into the market leading manufacturer of novel medicines such as MDMA, Psilocybin, and Cannabis.
- Sam is the CEO and founder of Breathe International Ltd, which became Bioxyne's largest shareholder following its all-share acquisition of BLS in 2023.

Jason Hine
BA Economics and Commerce
Executive Director

- Jason was previously the GM Commercial Operations for ECS Botanics Limited, Australia's largest medicinal cannabis and hemp food wellness business.
- Jason has been CEO, COO and Managing Director of a number of companies in various industries over a 30-year career.

Guy Robertson
B. Com (Hons.) CA
CFO & Company Secretary

- Guy is an experienced finance executive, having held the positions of Director, Company Secretary and Chief Financial Officer of both private and ASX-listed companies in Australia and Hong Kong.
- Guy held senior roles in the Jardine Matheson Group of Companies, including General Manager Finance of Franklins Limited, Chief Operating Officer of Colliers International Asia Pacific and Managing Director (NSW) Jardine Lloyd Thompson.

CORPORATE SNAPSHOT



CORPORATE SNAPSHOT (JULY-2025)	
Shares on Issue	2,164m
Options & Performance Rights	149.9m
Share price	$0.050
Market capitalisation	$108.2m
52-week high	$0.053
52-week low	$0.004

MAJOR SHAREHOLDERS

Shareholder	Shares (m)	%
Breathe International Ltd	576,268,527	26.62
KIRKMAN TRADING LTD	157,805,604	7.28
Ian Edward Owles	132,488,966	6.12
BNP PARIBAS NOMINEES PTY LTD	108,616,726	5.02
MR CHRISTOPHER PEACOCK	84,414,00	3.90
BPMGMT LTD	79,493,379	3.67
CITICORP NOMINEES PTY LTD	58,462,015	2.70
Zonetech Wellness Ltd	57,732,857	2.67
Paramount Star Investments Limited	36,000,000	1.66
Gavin James Ogilvie	35,528,354	1.62

CONTACT



JAMES EMONSON
ALPINE CAPITAL
Corporate Advisor
jemonson@alpinecapital.au